BIOS Health

BIOS Health operates at the intersection of neural engineering, medical devices, digital therapeutics and precision medicine. Its differentiation is the attempt to connect continuously measured neural and physiological signals with actionable biomarkers, then use those signals to personalize neuromodulation dosing. The product set spans neural data acquisition, machine-learning analysis, clinician-facing tools and remote patient monitoring rather than a single consumer application. That integrated approach gives BIOS a broader development platform than companies focused only on implant hardware, wearable monitoring or software-based behavioral therapy. The company’s stated initial emphasis on cardiac and autonomic conditions also distinguishes it from neurotechnology businesses centered primarily on brain-computer interfaces or motor prosthetics.

BIOS Health has followed a long research-to-platform trajectory since its founding on May 5, 2015. Early activity included grants and non-equity assistance in 2015-2017, followed by a $4.5 million seed round announced on Dec 4, 2018 and additional UK grant support totaling $1.14 million across the disclosed 2018 and 2019 grants. The major financing inflection points were the $21 million grant announced on Nov 3, 2022 and the $20 million Series A on Jun 22, 2023. A subsequent venture round on Jan 9, 2024 suggests continued financing, but its amount is undisclosed. Product development has expanded from neural signal acquisition into neural dosing, therapy development and remote patient monitoring, including wearable devices, mobile applications and clinician portals. The company currently lists five featured positions and is hiring across Cambridge and Montreal, indicating ongoing team building rather than contraction. Oliver Armitage’s move into a Senior Scientific Advisor role in February 2025 may reflect a shift toward scientific stewardship as the company scales. Still, limited public launch, revenue and clinical-commercialization data constrain assessment of near-term growth.